Table 1 Patient and treatment characteristics

From: Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

 

5-FU+MMC ( n =47)

Capecitabine+MMC ( n =58)

 

Characteristic

No.

%

No.

%

P -value

Age (years), median (range)

53.5 (36.8–83.8)

59.3 (41.3–86.4)

0.277

Gender

Male

23

49

22

38

0.322

Female

24

51

36

62

 

T-classification

T1

1

2

0

0

0.837

T2

20

43

29

50

 

T3

18

38

19

33

 

T4

8

17

10

17

 

N-classification

N0

22

47

18

31

0.103

N1

13

28

19

33

 

N2

9

19

9

16

 

N3

3

6

10

17

 

Nx

0

0

2

3

 

UICC stage

Stage 0

0

0

0

0

0.221

Stage I

0

0

0

0

 

Stage II

17

36

14

24

 

Stage III

30

64

42

72

 

Stage IV

0

0

0

0

 

Not known

0

0

2

3

 

Primary tumour site

Anal canal

40

85

50

86

0.957

Anal margin

5

11

5

9

 

Both

2

4

3

5

 

HIV status

Negative

12

26

27

47

0.078

Positive

7

15

4

7

 

Unknown

28

60

27

47

 

SCC tumour marker

Normal (<2.0 μg l−1)

24

51

36

62

0.223

Elevated (2.0 μg l−1)

22

47

19

33

 

Unknown

1

2

3

5

 

DPYD *2A genotype

Wild type

7

15

56

97

1.000

Heterozygous

0

0

1

2

 

Unknown

40

85

1

2

 

Radiation technique

CF-RT

24

51

0

0

IMRT

23

49

58

100

 

Radiation dose

Surdosage given?

5-FU+CF-RT

5-FU+IMRT

Capecitabine+IMRT

 

 Yes

24 (100%)

19 (83%)

32 (55%)

 No

0 (0%)

4 (17%)

26 (45%)

 

Total radiation dose to primary tumour, median (range)

64.8 (64.8–66.6)

64.8 (59.4–68.4)

64.8 (59.4–70.2)

Total radiation dose to LNs, median (range)

64.8 (45.0–66.6)

54.9 (49.5–58.5)

54.9 (49.5–60.3)

  1. Abbreviations: 5-FU=5-fluorouracil; CF-RT=three-dimensional conformal radiotherapy; HIV=Human immunodeficiency virus; IMRT=intensity-modulated radiation therapy; LNs=lymph nodes; MMC=mitomycin C; SCC=squamous cell carcinoma.